A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma

Trial Profile

A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Acronyms PC03
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 May 2013 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top